Results 191 to 200 of about 4,267,014 (280)

From cramming to binge‐watching: Integrating documentary‐based assessment into a pharmacology and toxicology curriculum—a qualitative study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims In the context of pharmacology and toxicology education, there is a growing shift toward programmatic assessment models that prioritize longitudinal learning, reflection and development of higher‐order cognitive skills. As part of this transition, we are exploring alternative and more meaningful forms of assessment. This qualitative study
Narin Akrawi   +2 more
wiley   +1 more source

Illustrating the Phaenomena: Celestial Cartography in Antiquity and the Middle Ages

open access: yesAestimatio, 2015
Elly Dekker (book author)   +1 more
doaj   +1 more source

More than words: The value of qualitative research for advancing educational practice

open access: yes
Anatomical Sciences Education, EarlyView.
Georgina C. Stephens   +1 more
wiley   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Diofanto, De polygonis numeris. Introduzione, testo critico, traduzione italiana e commento

open access: yesAestimatio, 2016
Fabio Acerbi (book author)   +1 more
doaj   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy